Energy Channel
HomeEnergyBriefing: Why Ionis Pharmaceuticals’ (IONS) 2026 Catalyst Pi…
Energy

Briefing: Why Ionis Pharmaceuticals’ (IONS) 2026 Catalyst Pipeline Supported Leerink’s Higher Target

Strategic angle: An analysis of Ionis Pharmaceuticals' upcoming catalysts and their impact on stock valuation.

Editorial StaffMarch 18, 20261 min read

Leerink raises target price for Ionis Pharmaceuticals.

Focus on 2026 catalyst pipeline as a key driver.

Market response to upcoming drug developments.